Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-11-09 | 2022-09 | -0.42 | N/A | N/A | N/A |
2022-08-08 | 2022-06 | -0.42 | N/A | N/A | N/A |
2022-05-04 | 2022-03 | -0.43 | N/A | N/A | N/A |
2022-02-23 | 2021-12 | -0.6 | N/A | N/A | N/A |
2021-11-03 | 2021-09 | -0.48 | N/A | N/A | N/A |
2021-08-04 | 2021-06 | -0.57 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-10 | JP Morgan | Downgrade | Neutral | Underweight |
2022-05-06 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2022-05-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-09-21 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-05-05 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-11-01 | GROSS PAUL EDWARD | General Counsel | 98.33K | Sale |
2022-11-01 | HARDING THOMAS C | Officer | 0.00 | Sale |
2022-11-01 | IVERS-READ GILLIAN C | Officer | 293.61K | Sale |
2022-11-01 | MUEHL DANIEL W | Chief Financial Officer | 104.83K | Sale |
2022-11-01 | ROLFE LINDSEY | Officer | 113.69K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Group, Inc. (The) | 10.21M | 828.77K | 7.04% |
2022-09-29 | Palo Alto Investors Lp | 4.47M | 363.29K | 3.09% |
2022-09-29 | Blackrock Inc. | 4.04M | 327.67K | 2.78% |
2022-09-29 | QVT Financial LP | 3.53M | 286.23K | 2.43% |
2022-09-29 | Renaissance Technologies, LLC | 2.21M | 179.43K | 1.52% |
2022-09-29 | Geode Capital Management, LLC | 1.38M | 112.30K | 0.95% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Total Stock Market Index Fund | 4.34M | 352.67K | 3.00% |
2022-09-29 | Vanguard Extended Market Index Fund | 1.92M | 155.70K | 1.32% |
2022-09-29 | Vanguard Strategic Equity Fund | 1.68M | 136.34K | 1.16% |
2022-07-30 | Vanguard Explorer Fund, Inc. | 1.44M | 116.87K | 0.99% |
2022-11-29 | iShares NASDAQ Biotechnology ETF | 1.17M | 94.72K | 0.80% |
2022-10-30 | Fidelity Extended Market Index Fund | 747.38K | 60.69K | 0.52% |
-
This Share is this way... because this too much tipped off its future rise.
-
Be careful with the Short Term. They’re Dangerous!!!!!!!!!
-
Perfect!! $SMART$9. CVLS. ...I Hope that’s it. Thanks for explain tendency.
-
Excellent!! Comment. $Smart9$X. I think so...Agree. Tk’s a lot. $Clvs35$.
-
BRAVO!! $SMART9$. For your observation about CLOVIS. You are the best...
-
You Take advantage of buying this Share CHEAPER, that will not return to that price at a certain time... projection 23$. #CVLS
-
I shit on the short term!!! They don't let action act freely. I'd be at $13.5. Puta Madre
-
Keep going men!! 11$.
-
Good read on how to keep your broker from using your shares to short. Place limit order at 20!
Https://www.contracts-for-difference.com/Borrowing-lending-shares.html
-
$MART9X. Excellent!! ....Congratulations. I Bought 13,5 December 3. Keep going... $30. BO.
-
A good council... There's Clovis action this sub - valued. It has all the tools to be on a price of three or four times its current price price reminder of its price in the last issue of shares 9.29 $27/30.
-
Big boy’s are toying with the little guys they will drive it up soon enough
-
There's a group that manipulates the action and bails it down... This action without these manipulations would be $13... it's bugs.
-
Honestly! Clovis has the full potential to gain more ground ground in its price per share:
- Cost Per Action 9,25$ inside (Value 3 times more).
- Outside 9.19$ (4pm). Last Friday. (manipulated). Traders.
- Official approval and publication soon.sDNA. Unique.
- EPS-between 1,56/1,66 versus 1,88. estimates . 4th. Quarter.
- Increase in sales.
- Dilute loss of current year and previous year.
- JPM - News CLVS.
- target projection 26/32 $.
-
****Los que bajaron la Accion ... Es una BANDA “. Son una PILA DE MALANDROS. Jugando con el mercado. ....No se justifica su Caida. *****CDSM
*****The ones who came down... It's a band . They're a pile of malanders. Playing with the market... No justification for your downfall.****MF.
-
$MART. Enjoy.!! Thank a lot. For the TIPS. Have nice Weekend.
-
Going’s to green
-
Clovis Oncology (NASDAQ:CLVS) to Post FY2024 Earnings of ($0.04) Per Share, Piper Sandler Forecasts
Posted by Clara Ruiz on Jan 9th, 2020
Clovis Oncology logo
Clovis Oncology (NASDAQ:CLVS) – Equities researchers at Piper Sandler issued their FY2024 earnings per share estimates for Clovis Oncology in a research note issued on Tuesday, January 7th. Piper Sandler analyst J. Catanzaro forecasts that the biopharmaceutical company will post earnings of ($0.04) per share for the year. -
Tk’s MAR$9. For News.
-
It's coming the best!! The plate. The good news of the Aprobación SNDA. + jp Morgan conference - MONDAY + Revenues And EPS. Projection $26. believe it!! Enjoy